Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657245 | 1.00 | HPGD (0.56) | HPGDRAB9ALMNAHTTNPC1 | |
| SCHEMBL14409007 | 0.87 | HPGD (0.59) | HPGDRAB9ALMNANPC1KDM4E | |
| SCHEMBL2219210 | 0.82 | HPGD (0.49) | HPGDRAB9ALMNANPC1CASR | |
| SCHEMBL23374717 | 0.79 | HPGD (0.58) | HPGDRAB9ALMNANPC1KDM4E | |
| SCHEMBL2215734 | 0.79 | MAPT (0.52) | RAB9ALMNANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15654005 | 0.79 | MAPT (0.52) | RAB9ALMNANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14416100 | 0.79 | HPGD (0.64) | HPGDRAB9ALMNANPC1KDM4E | |
| SCHEMBL15653617 | 0.78 | GFER (0.47) | HPGDRAB9ALMNANPC1ALDH1A1 | |
| SCHEMBL2219204 | 0.78 | GFER (0.47) | HPGDRAB9ALMNANPC1ALDH1A1 | |
| SCHEMBL12608407 | 0.76 | HPGD (0.65) | HPGDRAB9ALMNANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | claimed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | claimed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2009051718-A2 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | CASR, CALCR, RYR1 | HPGD 1840/4885RAB9A 1113/4885LMNA 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.